Comparative Pharmacology
Head-to-head clinical analysis: LICART versus XYLOCAINE 4 PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LICART versus XYLOCAINE 4 PRESERVATIVE FREE.
LICART vs XYLOCAINE 4% PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Licart is a fibrin sealant containing human fibrinogen and thrombin. When applied, thrombin converts fibrinogen to fibrin, forming a stable clot that mimics the final stage of coagulation. It also contains factor XIII and aprotinin to cross-link fibrin and inhibit fibrinolysis, respectively.
Lidocaine stabilizes the neuronal membrane by inhibiting sodium ion influx through voltage-gated sodium channels, thereby blocking the initiation and propagation of action potentials, resulting in local anesthesia.
Adults: 50 mg orally once daily.
Maximum 4.5 mg/kg (not to exceed 300 mg) via subcutaneous infiltration, epidural, or nerve block; repeat dosing after 30 minutes if needed.
None Documented
None Documented
Terminal elimination half-life of 6-8 hours in adults with normal renal function. Prolonged in renal impairment (up to 20-24 hours in ESRD), requiring dose adjustment in CrCl <30 mL/min.
Terminal elimination half-life: ~1.5–2 hours (adults). Prolonged in hepatic impairment, congestive heart failure, or neonates.
Primarily renal excretion (80-85% as unchanged drug), with 10-15% biliary/fecal elimination. Less than 5% metabolized to inactive glucuronide conjugate.
Renal: ~90% as metabolites (mostly 4-hydroxy-2,6-xylidine and conjugates); <10% unchanged. Biliary/fecal: minor.
Category C
Category C
Local Anesthetic
Local Anesthetic